Aurora Cannabis Inc (ACB.TO) is seeing a notable rise in its stock price, thanks to recent positive developments in the cannabis sector.
Today, Aurora's stock jumped 15.63%, closing at CA$4.66. This increase is largely due to good news about the company's international medical cannabis sales.
Advertisement
Aurora Cannabis Inc
ACB.TO
ACB.TO
Aurora Cannabis Inc
WealthAwesomeAdvertisement
Market cap
$257.06M
52W high
$9.33
52W low
$3.59
1W change
+3.87%
Beta
1.34
Analyst Price Targets
Based on analyst covering ACB
Wall Street analysts forecast ACB stock price to rise 38.0% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$5.56
+38.0% Upside
Current Price
C$4.03
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Advertisement
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on ACB's historical volatility
30-Day Vol
36.0%
Annualized
90-Day Vol
47.6%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$3.37
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$3.80 | C$3.35 – C$4.30 |
| 60 trading days | C$3.58 | C$3.00 – C$4.27 |
| 90 trading days | C$3.37 | C$2.72 – C$4.18 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Investor takeaway: Investors are reacting positively to Aurora's focus on international markets, which is helping to offset losses from its Canadian operations.
15.63% Gain in One Day
Aurora's stock experienced a significant boost today, reflecting investor optimism after a reduction in quarterly losses and growth in international markets.
Bull case
The rise in international medical cannabis revenue, especially in Germany, indicates strong demand that could lead to ongoing profitability for Aurora Cannabis in the future.
Bear case
Despite today's gains, Aurora's consumer cannabis segment is still declining sharply, raising concerns about the company's overall market position and revenue diversification.
Positive Developments in the Cannabis Sector
Advertisement
Aurora's recent performance is supported by a broader positive trend in the cannabis industry. Reports show that international medical cannabis sales are gaining momentum, particularly in Europe. This growth is vital for Aurora, which has been focusing on international markets to counteract declines in its domestic consumer cannabis business.
International Sales Driving Revenue
In its latest quarterly report, Aurora highlighted a significant increase in international medical cannabis revenue, particularly from Germany. This shift in focus is helping the company reduce its losses as it navigates a tough domestic market where Canadian medical cannabis revenue has been falling due to changes in reimbursement policies.
Outlook for Investors
While today's gains are promising, investors should remain cautious. The ongoing decline in Aurora's consumer cannabis segment raises questions about the company's long-term growth strategy. As Aurora shifts its focus to international markets, the sustainability of today's stock surge will depend on its ability to keep up this momentum in the coming quarters. For more insights, check out our detailed analysis on Aurora Cannabis Inc.
Advertisement
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
